Skip to main content
    W

    Wellgistics Health, Inc. Common Stock (WGRX)

    Official site

    PHARMACEUTICAL RETAILERS

    $3.52
    +0.81 (+29.89%)

    Last updated: Jul 21, 2026 at 5:00 PM ET

    Wellgistics Health, Inc. Common Stock (WGRX) Financials: Revenue, Profit and Cash Flow

    Updated Sep 30, 2026. Financial statements from company filings, amounts in US dollars.

    Wellgistics Health, Inc. Common Stock reported revenue of $23.34M for the fiscal year ended Dec 31, 2025, up 28.7% from the year before. That year, net income was -$101.27M with a net margin of -433.9%, operating cash flow was -$10.86M and free cash flow was -$11.74M. The quarter ended Sep 30, 2026 had revenue of $2.67M and net income of $10.54M.

    Revenue and Margins

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$23.34M+28.7%-27.5%-401.7%-433.9%
    Dec 2024$18.13MN/A9.7%-33.9%-37.8%
    Dec 2023$0-100.0%N/AN/AN/A
    Dec 2022$32.78MN/A17.5%-10.4%-8.4%
    Annual, fiscal years ended Dec 2022 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022
    Revenue$23.34M$18.13M$0$32.78M
    Cost of revenue$29.76M$16.36M$0$27.03M
    Gross profit-$6.43M$1.77M$0$5.75M
    Research and development$0$0$0$1.40K
    Operating income-$93.75M-$6.15M-$2.88M-$3.42M
    Net income-$101.27M-$6.86M-$2.90M-$2.74M
    EBITDA-$90.46M-$4.91M-$2.88M-$369.03K
    Fiscal years ended Dec 2022 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$2.67M$1.78M$1.56M$1.67M$3.01M$7.79M$10.86M$12.41M$5.67M$44.54K$0$34.37M
    Gross profit$431.88K$182.20K$170.22K-$7.86M$231.01K$505.75K$692.64K$1.25M$521.24K-$2.61K$0$2.77M
    Operating income-$3.37M-$7.35M-$6.02M-$25.35M-$31.55M-$5.50M-$31.35M-$3.75M-$1.74M-$573.02K-$79.76K-$10.32M
    Net income$10.54M-$18.36M-$7.74M-$27.85M-$34.32M-$6.67M-$32.43M-$4.33M-$1.87M-$574.33K-$83.12K-$11.80M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $23.49M exceeded cash and equivalents by $23.44M. Shareholder equity was negative, at -$12.45M, as total liabilities of $42.91M exceeded total assets of $30.46M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022
    Total assets$30.46M$57.33M$338.36K$0
    Current assets$2.82M$15.17M$338.36K$0
    Cash and equivalents$42.57K$1.03M$1.36K$0
    Total liabilities$42.91M$50.60M$3.24M$5.25K
    Short-term debt$10.89M$11.93M$0N/A
    Long-term debt$12.60M$11.46M$350.00KN/A
    Shareholder equity-$12.45M$6.73M-$2.90M-$5.25K
    Fiscal years ended Dec 2022 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$38.73M$32.76M$30.13M$30.46M$52.78M$54.23M$58.06M$57.33M$55.57M$44.66M$34.68M$338.36K
    Total liabilities$38.56M$52.26M$45.19M$42.91M$46.00M$53.32M$53.58M$50.60M$45.59M$45.62M$34.68M$3.24M
    Cash and equivalents$476.60K$2.46M$51.73K$42.57K$4.23M$419.94K$2.52M$1.03M$793.15K$2.07M$917.14K$1.36K
    Shareholder equity-$1.70M-$19.50M-$15.06M-$12.45M$6.78M$905.25K$4.48M$6.73M$9.99M-$967.13K-$93-$2.90M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022
    Operating cash flow-$10.86M-$1.22M-$349.14K$0
    Capital expenditures$881.53K$377.29K$0$0
    Free cash flow-$11.74M-$1.60M-$349.14K$0
    Investing cash flow-$881.53K$469.07K$0N/A
    Financing cash flow$10.75M$1.78M$350.50K$0
    Fiscal years ended Dec 2022 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$2.90M-$2.89M-$3.41M-$6.29M-$1.14M-$2.08M-$1.35M-$2.62M$1.04M$329.96K$31.24K-$462.06K
    Capital expendituresN/AN/A$205.10K$255.38K$405.06K$131.93K$273.13K$112.44K$217.05K$4$3$0
    Free cash flowN/AN/A-$3.62M-$6.55M-$1.54M-$2.21M-$1.62M-$2.74M$820.54K$329.95K$31.23K-$462.06K
    Last 12 quarters

    Frequently Asked Questions About WGRX

    What is Wellgistics Health, Inc. Common Stock's annual revenue?

    Wellgistics Health, Inc. Common Stock reported revenue of $23.34M for the fiscal year ended Dec 31, 2025.

    How fast is Wellgistics Health, Inc. Common Stock's revenue growing?

    Revenue was up 28.7% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is Wellgistics Health, Inc. Common Stock profitable?

    No. Wellgistics Health, Inc. Common Stock reported net income of -$101.27M for the fiscal year ended Dec 31, 2025, with a net margin of -433.9%.

    How much free cash flow does WGRX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$10.86M minus capital expenditures of $881.53K produced free cash flow of -$11.74M.

    How much debt does Wellgistics Health, Inc. Common Stock have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $12.60M, short-term debt of $10.89M and cash and equivalents of $42.57K.